

Protalix BioTherapeutics, Inc.
Form 8-K
April 07, 2011

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): April 7, 2011

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Florida
**(State or other jurisdiction
of incorporation)**

001-33357
(Commission File Number)

65-0643773
**(IRS Employer
Identification No.)**

2 Snunit Street
Science Park, POB 455
Carmiel, Israel
(Address of principal executive offices)

20100

(Zip Code)

Registrant's telephone number, including area code +972-4-988-9488
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 2(b)
- Pre-commencement communications pursuant to Rule 4(c)

Item 7.01. Regulation FD Disclosure

On April 7, 2011, Protalix BioTherapeutics, Inc. (the Company) issued a press release announcing that Yossi Maimon, the Company s Chief Financial Officer, will present at the Tel Aviv Stock Exchange 100 investment conference on Tuesday, April 12, 2011 at the Hilton Tel Aviv in Israel. A copy of the press release is attached hereto as Exhibit 99.1. The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated April 7, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX BIOTHERAPEUTICS, INC.

Date: April 7, 2011

By: /s/ David Aviezer
Name: David Aviezer, Ph.D.
Title: President and Chief Executive
Officer